Delivery Order SPE2DB22D3501-SPE2DB25FWU63
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,342.70 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). This firm fixed price contract, issued on August 15, 2025, represents a competitively awarded procurement with no set-aside designation and an ultimate completion date of August 18, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,790.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). The contract, which is a non-set-aside competitive award with an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order will be fulfilled from the vendor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,235.22 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's pharmaceutical supply services to the federal government and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract is for the supply of Ropivacaine 0.2% 200 mg/100 mL, a local anesthetic medication, with a ceiling value of $1,029.75 and an ultimate completion date of August 29, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a wholly owned subsidiary of Amerisourcebergen Corporation, to provide 4556997205 - Ropivacaine 0.2% 200 mg/100 ml 100 ml pharmaceuticals. The contract award, valued at $2,695.54, has an ultimate completion date of April 27, 2022. This delivery order is issued under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp, valued up to $999,999,999.00 with a...
- The Defense Logistics Agency awarded a $3,869.49 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 400 mg/200 ml vials of ropivacaine hydrochloride injection 0.2%. The single day contract calls for Amerisourcebergen to deliver the anesthetic to its Conshohocken, Pennsylvania facility from September 5-6, 2023. As a major supplier of pharmaceuticals and medical supplies to the U.S. military and other government agencies, Amerisourcebergen was likely awarded this delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,731.07, is for the supply of 400 mg/200 mL ropivacaine 0.2% injectable medication. The contract has a firm fixed price pricing type and an ultimate completion date of March 8, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
- This is a $1,607.68 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 400 mg/200 mL of the anesthetic drug ropivacaine 0.2%. The contract does not have a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This contract award is for the delivery of 400 mg/200 mL vials of ropivacaine 0.2% solution, a local anesthetic medication, to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order, valued at $3,873.51, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of October 27, 2023 and is not set aside for any specific business category. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 0.2% Ropivacaine, a local anesthetic medication, with a ceiling value of $1,608.24 and a completion date of July 18, 2025. The contract is a firm fixed price delivery order, with no set-aside designation, indicating it was competitively awarded. Amerisourcebergen Drug Corp...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWU63Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,646.08 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml), a local anesthetic pharmaceutical product. The contract, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical supply vehicle for military and federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was competitively selected to fulfill this medical supply requirement. The company maintains an extensive portfolio of federal contracts with the DLA Medical Supply Chain, supplying a broad range of pharmaceutical products and medical supplies to support military healthcare programs and other government healthcare systems. This transaction exemplifies the routine delivery order activity generated under the company's prime vendor agreement, enabling efficient procurement of critical pharmaceutical commodities necessary for federal medical operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 8/11/25 |